Aarkstore 2012 The Latest Report || Pricing and Reimbursement in the US - Non-LIS Beneficiaries || Global Market Research

FOR IMMEDIATE RELEASE
(Free-Press-Release.com) February 1, 2012 -- Aarkstore.com announces, a new market research report is available in its vast collection:
Pricing and Reimbursement in the US - Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from Reduction in Out-of-Pocket Expenditure for Generic Drugs

http://www.aarkstore.com/reports/Pricing-and-Reimbursement-in-the-US-Non-LIS-Beneficiaries-Not-Covered-by-Medicare-Coverage-Gap-to-Gain-from-Reduction-in-Out-of-Pocket-Expenditure-for-Generic-Drugs-185603.html



Summary

Company, the leading business intelligence provider, has released its latest research “Pricing and Reimbursement in the US - Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from Reduction in Out-of-Pocket Expenditure for Generic Drugs”. The report provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in the US with key data, information and analysis of pricing and reimbursement decisions across the US. The report closely scrutinizes major changes in pharmaceuticals-related pricing and reimbursement in the US in the recent past and the impact these changes will have in the future. It also describes the efforts taken by the US government and private sector in shaping the pricing and reimbursement policies of brand name and generic drugs. The pricing and reimbursement scenario in some of the major therapy areas of the US has been described with the help of informative case studies.

Scope
- Detailed study of the healthcare systems in the US.
- Political, economical, social and technological analysis of the US pharmaceutical industry.
- Analysis of the pricing and reimbursement mechanisms in the US.
- Key trends that follow from the recent changes brought about in the pricing and reimbursement system.
Table of Contents :
1.1 List of Tables 5
1.2 List of Figures 6
2 Pricing and Reimbursement in the US - Introduction 7
2.1 Company Report Guidance 8
3 Healthcare System in the US - Overview 9

3.1 Healthcare Expenditure 9
3.1.1 Healthcare Expenditure and GDP 9
3.1.2 Healthcare Expenditure by Category 13
3.2 Healthcare Infrastructure 19
3.2.1 Hospitals 19
3.2.2 Hospital Beds 20
3.2.3 Healthcare Professionals 20
3.3 Health Insurance 21
3.3.1 Health Insurance Coverage 21
3.3.2 Health Insurance Providers 22
3.4 Demographic Trends Affecting Healthcare 26
3.4.1 Population Demography 26
4 Pharmaceutical Regulations in the US - Overview 28
4.1 Pharmaceutical Industry in the US 28
4.1.1 PEST Analysis 28
4.2 Healthcare Regulation 30

4.2.1 Highlights of the Budget 2011-2012 31
5 Pricing of Pharmaceutical Drugs in the US 33
5.1 Pricing Overview 33
5.1.1 Regulatory Bodies 34
5.1.2 Pricing Control 34
5.1.3 340B Drug Pricing Program 35
5.2 Key Trends 35
5.2.1 Brand Name Drug Prices Increase in the Face of Generic Competition 35
5.2.2 Significant Decrease in Average Price of Generic Drugs 36
5.2.3 PPACA Introduced by the US President to Tackle Soaring Prescription Drug Prices 37
5.2.4 Generic Price War at Retail Sector 39
5.3 Major Challenges 40
5.3.1 Reducing Wastage in Healthcare Spending 40

For all Related Reports Please follow the link:
http://www.aarkstore.com/search/viewresults.asp?search=Pricing and Reimbursement&PubId=&pagenum=1

More Reports:
BRC DiamondCore Ltd. (BCD) - Financial and Strategic SWOT Analysis Review

Orthopedic Devices Market in the Emerging Countries (China, India, Brazil) - Greater Focus on Minimally Invasive Orthopedic Procedures to Drive the Market

Oncology Devices Market to 2017 - Improved Efficiency, Shorter Treatment Times and Cost-Effectiveness to Boost the Brachytherapy Devices Segment

Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted




For more information kindly visit:

Contact: Marketing Team

Ph.No.918149852585

Email : enquiry@aarkstore.com/
URL: http://www.aarkstore.com/

PricingReimbursement